The Dec. 17-18 joint meeting of the US FDA’s Anesthetic & Analgesic Drugs Products and Drug Safety & Risk Management Advisory Committees was probably the single most unusual and creative use of the advisory committee format by the agency’s new drug review center.
The formal discussion topic was itself unusual, but well within the boundaries of advisory committee fare: whether FDA should consider...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?